Objective:

To analyze the implications of the UK-EU withdrawal agreement on the pharmaceutical industry.

Approach:

• Expert Opinions: Three experts provide insights on the potential impact of the withdrawal agreement on pharmaceutical companies.

Key Findings:

• The withdrawal agreement includes a 21-month transition period, which may be extended, allowing time for further negotiations.
• If ratified, the agreement aims to prevent a 'hard Brexit' and maintain the free movement of goods during the transition.
• Concerns remain regarding regulatory divergence and the validity of UK marketing authorizations in the EU post-Brexit.
• The political declaration suggests potential cooperation with EU regulatory agencies, which could benefit the pharmaceutical sector.

Interpretation:

Limitations:

• The deal's ratification is uncertain, and rejection could lead to a more chaotic Brexit scenario.
• The agreement does not guarantee participation in the EMA for UK-based companies.
• Regulatory checks at borders may still disrupt logistics for pharmaceutical products.

Conclusion:

Sources:

• Eisai Europe
• Institute for Government